Ann: Quarterly Shareholder Update - December 2017, page-11

Not sure I agree as I don't want them to try and flog the company now. What sort of a premium do you think they will get? Even at a 100%, it isn't going to be that great. They have to slowly build up revenues from Bronchitol and Aridol while progressing the Phase II's and the rest of the pipeline. That is what they are doing.

The SP is out of their control IMO. Maybe they can go drum up interest by presenting at various conferences, getting brokers to produce more research reports but I would rather they focus on achieving results and the SP will eventually come through. Sometimes it takes time and this company has had quite a few missteps in its past. Many holders have long memories.

I think LOXL2 will be this catalyst to break the SP from its doldrums. If they do a deal with a different pharma, it will validate the platform even further and could create competitive tension between BI.